Calidi Biotherapeutics, Inc. (CLDI)
NYSE American · Healthcare · Biotechnology
$1.05−2.78%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.9M
- 52-week range
- $1.03 – $27.84
- 52-week change
- −95.78%
- EPS (trailing)
- −$35.46
Fiscal year to Dec 2025
- Net income
- −$19.9M
- Diluted EPS
- −$5.95
From the company’s annual report on SEC EDGAR.
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 29 employees · calidibio.com